Evidence map›Paper›PMID 39444066›Full record

ReviewSmall (Weinheim an der Bergstrasse, Germany)2025

Engineering Stimuli-Responsive Materials for Precision Medicine.

Ruixuan Zheng, Chang Yu, Dan Yao, Mengsi Cai, Lexiang Zhang, Fangfu Ye, Xiaoying Huang

Abstract readReview
In one paragraph

Review in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Supramolecular Degraders: An Emerging Paradigm in Targeted Protein Degradation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Engineering Stimuli-Responsive Materials for Precision Medicine.Small (Weinheim an der Bergstrasse, Germany) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ruixuan ZhengJoint Centre of Translational Medicine, Division of Pulmonary Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Chang YuWenzhou Key Laboratory of Interdiscipline and Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University Wenzhou, Wenzhou, Zhejiang, 325000, China.
Dan YaoJoint Centre of Translational Medicine, Division of Pulmonary Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Mengsi CaiJoint Centre of Translational Medicine, Division of Pulmonary Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Lexiang ZhangJoint Centre of Translational Medicine, Division of Pulmonary Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Fangfu YeJoint Centre of Translational Medicine, Division of Pulmonary Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Xiaoying HuangJoint Centre of Translational Medicine, Division of Pulmonary Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.ORCID 0000-0003-4854-0922

Funding

Basic scientific research Project of Wenzhou H20210010Key Projects of Wenzhou Science and Technology Bureau 2023W0006Key Projects of Wenzhou Science and Technology Bureau ZG2023013Key Projects of Wenzhou Science and Technology Bureau ZN2024009Key Research and Development Plan of Zhejiang Province "Spearhead" 2022C03007National Key Research and Development Program of China 2020YFA0908200National Natural Science Foundation of China 12325405National Natural Science Foundation of China 22307098National Natural Science Foundation of China T2221001"Pioneer" and "Leading Goose" R&D Program of Zhejiang 2023C03030Strategic Priority Research Program of Chinese Academy of Sciences XDB33000000the program of WIUCASQD2021012 from Wenzhou InstituteUniversity of Chinese Academy of SciencesWenzhou Basic Research Projects Y2023147Zhejiang Provincial Natural Science Foundation of China LGF22C100003
6 · The paper itself

Abstract

Over the past decade, precision medicine has garnered increasing attention, making significant strides in discovering new therapeutic drugs and mechanisms, resulting in notable achievements in symptom alleviation, pain reduction, and extended survival rates. However, the limited target specificity of primary drugs and inter-individual differences have often necessitated high-dosage strategies, leading to challenges such as restricted deep tissue penetration rates and systemic side effects. Material science advancements present a promising avenue for these issues. By leveraging the distinct internal features of diseased regions and the application of specific external stimuli, responsive materials can be tailored to achieve targeted delivery, controllable release, and specific biochemical reactions. This review aims to highlight the latest advancements in stimuli-responsive materials and their potential in precision medicine. Initially, we introduce disease-related internal stimuli and capable external stimuli, elucidating the reaction principles of responsive functional groups. Subsequently, we provide a detailed analysis of representative pre-clinical achievements of stimuli responsive materials across various clinical applications, including enhancements in the treatment of cancers, injury diseases, inflammatory diseases, infection diseases, and high-throughput microfluidic biosensors. Finally, we discuss some clinical challenges, such as off-target effects, long-term impacts of nano-materials, potential ethical concerns, and offer insights into future perspectives of stimuli-responsive materials.

Indexed as

Precision MedicineAnimalsDrug Delivery SystemsHumansmicrofluidic biosensorsprecision medicinestimuli‐responsive materialstargeted drug delivery

Identifiers

PMID39444066
PMCPMC11707583

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.